[PRNewswire] Vela Diagnostics with SRL Inc. for Product Distribution in Japan
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
Dr Tony Zhang, Head of Research and Development at Vela Diagnostics, states that SRL Inc has begun feasibility studies for the Sentosa® SQ HIV-1 Genotyping Assay Kit. "The Sentosa® SQ HIV-1 Genotyping Assay is VELA's premier solution for automated Next-Generation Sequencing (NGS) of HIV-1, granted FDA DeNovo designation in 2019," explained Dr Zhang. "With its lower hands-on time and improved turnaround time compared to other kits on the market, the assay combines efficiency of NGS techniques with a unique sensitivity to mutations in three key drug targets. It provides critical insights into the virus's drug resistance profile, potentially revolutionizing HIV testing in Japan."
"We are thrilled to partner with SRL Inc," said Sam Dajani, CEO of Vela Diagnostics "Japan offers tremendous opportunities, and we are confident that SRL Inc's extensive network and expertise will augment our ability to deliver innovative products to patients and healthcare providers in the region. We envision Japan joining the global network of HIV providers utilizing Vela Diagnostics' NGS assay kits spanning North and South America, Africa, Europe, the Middle East, South-East Asia and Australia. Together with SRL Inc, we anticipate a fruitful partnership that will improve patient outcomes and contribute to the global fight against HIV."
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
FAIRFIELD, N.J. Oct. 3, 2023 /PRNewswire=연합뉴스/ -- Vela Diagnostics announced today a research collaboration with SRL Inc, a premier Japanese healthcare service company. This partnership aims to facilitate the distribution of Vela Diagnostics' cutting-edge molecular diagnostic solutions in Japan.
Established in 1970, SRL Inc (a subsidiary of H.U Group Holdings Inc.), is a renowned clinical laboratory testing company in Japan with over 80 nationwide business bases, SRL Inc specializes in complex testing and serving prestigious customers, providing diagnostic solutions for diseases, treatment planning, monitoring post-treatment prognosis, and health checkups.
The research collaboration agreement (RCA) between Vela Diagnostics and SRL Inc was signed in June 2023, marking a significant milestone in their shared commitments to advancing healthcare solutions in Japan. Vela Diagnostics aims to capitalize on SRL Inc's comprehensive distribution network and market understanding, enabling the company to introduce its Sentosa® SQ HIV-1 Genotyping Assay Kit to Japanese healthcare and diagnostic institutions.
Dr Tony Zhang, Head of Research and Development at Vela Diagnostics, states that SRL Inc has begun feasibility studies for the Sentosa® SQ HIV-1 Genotyping Assay Kit. "The Sentosa® SQ HIV-1 Genotyping Assay is VELA's premier solution for automated Next-Generation Sequencing (NGS) of HIV-1, granted FDA DeNovo designation in 2019," explained Dr Zhang. "With its lower hands-on time and improved turnaround time compared to other kits on the market, the assay combines efficiency of NGS techniques with a unique sensitivity to mutations in three key drug targets. It provides critical insights into the virus's drug resistance profile, potentially revolutionizing HIV testing in Japan."
"We are thrilled to partner with SRL Inc," said Sam Dajani, CEO of Vela Diagnostics "Japan offers tremendous opportunities, and we are confident that SRL Inc's extensive network and expertise will augment our ability to deliver innovative products to patients and healthcare providers in the region. We envision Japan joining the global network of HIV providers utilizing Vela Diagnostics' NGS assay kits spanning North and South America, Africa, Europe, the Middle East, South-East Asia and Australia. Together with SRL Inc, we anticipate a fruitful partnership that will improve patient outcomes and contribute to the global fight against HIV."
About Vela Diagnostics
Vela Diagnostics is a leading provider for integrated IVD system solutions, from sample to result. VELA's test solutions utilize the automated Sentosa platform, providing the unique ability to leverage one system for NGS and PCR testing in infectious disease and oncology.
ⓒ 2023 Vela Diagnostics Holding Pte Ltd. All rights reserved. Sentosa® is a registered trademark of Vela Diagnostics Holding Pte Ltd outside Singapore in several markets including the US, EU, PRC and the UK. All Sentosa products listed above are by Vela Diagnostics.
Source: Vela Diagnostics
[편집자 주] 이 보도자료는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았으며, 연합뉴스의 편집방향과는 무관함을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
Copyright © 연합뉴스 보도자료. 무단전재 및 재배포 금지.
- 추석 20대 성수품…과일·한웃값 내리고 조기·배추·무 올라 | 연합뉴스
- '추석연휴 화상환자' 3배 더 많은데…일주일새 응급실 더 악화 | 연합뉴스
- 스트레스DSR에 만기도 축소…연봉1억 부부, 대출한도 1.3억 깎여 | 연합뉴스
- 지붕 뚫리고, 차 불나고…석 달간 날린 北오물풍선에 억대 피해 | 연합뉴스
- 교육교부금, 4년간 20조 불어난다…증가속도, 총지출의 갑절 | 연합뉴스
- "이스라엘군, 서안서 비무장 자원봉사 미국여성 머리에 총쐈다" | 연합뉴스
- 홍명보 "비난은 감독이 받으면 돼…경기장에선 선수 응원해달라" | 연합뉴스
- 공전하는 배달플랫폼 상생 협의…'100만원 벌면 20만원 수수료' | 연합뉴스
- 외국선 돌봄·직업훈련에도 지급…"국민연금 크레딧 추가해야" | 연합뉴스
- 누군가 보낸 나체 사진에 화들짝…'온라인 바바리맨' 활개 | 연합뉴스